Alemtuzumab‐induced petechiae and epistaxis in a patient with relapsing–remitting multiple sclerosis: A case report

Key clinical message Here, we present a case of relapsing–remitting multiple sclerosis that experienced petechiae and epistaxis following treatment with second dose of alemtuzumab. This study highlights such effects, emphasizing the need for vigilance as alemtuzumab usage increases. Timely recognition and management are vital for patient care.